In the spirit of World Cup competition, we're holding our own tournament in search of the Better Stock Today. We're pitting 32 companies against each other and you, the reader, will determine the winner.
LinkedIn takes on Isis Pharmaceuticals for this first round-robin match up in our search for the better stock today.
Motley Fool tech analyst, Jamal Carnette, thinks LinkedIn (NYSE:LNKD) should advance to the next round because of one big reason, the company is in the initial phases of redefining the job growth market. In the global search for talent, LinkedIn is the go-to place for both job seekers and employers. And while LinkedIn is busy disrupting this market, Mr. Market has sold off the stock. So, if you are looking for a true disruptor, LinkedIn deserves to advance.
David Williamson, Motley Fool health care analyst, thinks Isis Pharmaceuticals (NASDAQ:IONS) should advance to the next round because of one big reason -- its amazing drug pipeline. Wall Street heralds it as the best in biotech and puts Isis in play as a takeover target. A virtual who's who of big pharma has struck partnership deals. Isis already has orphan drug Kynamro on the market, and has seen recent success from a mid-stage study for an anti-clotting drug. A recent sell-off has given investors a chance to get this deep pipeline at a discounted price.
Warren Buffett vs. His Worst Nightmare
Warren Buffett just called this emerging technology a "real threat" to his biggest cash-cow. While Buffett shakes in his billionaire-boots, only a few investors are embracing this new market which experts say will be worth over $2 trillion. It won't be long before everyone on Wall Street wises up, that's why The Motley Fool is releasing this timely investor alert. Click here to learn more about what's keeping Buffett up at night and the one public company we're calling the "brains behind" the technology.
Vote here to determine the winner of this match and sound off in the comments. Check back to Fool.com to see who advances in the tournament.
David Williamson owns shares of LinkedIn. Jamal Carnette has no position in any stocks mentioned. The Motley Fool recommends Isis Pharmaceuticals and LinkedIn. The Motley Fool owns shares of LinkedIn. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.